How Life Sciences AI Implementation Actually Works Under GxP
The gap between deploying an AI model in a tech startup and implementing one in a GxP-regulated pharmaceutical environment is vast, often underestimated, and filled with regulatory landmines that have derailed countless promising initiatives. While the business case for AI in drug discovery, clinical development, and manufacturing is compelling, the reality of bringing these systems into validated production environments involves navigating a complex web of 21 CFR Part 11 requirements, ICH guidelines, and data integrity principles that most AI practitioners have never encountered. Understanding how this actually works—not the idealized version presented in vendor whitepapers, but the day-to-day reality of validation protocols, audit trail requirements, and FDA inspection readiness—is essential for anyone tasked with bridging the gap between innovation and compliance. The journey of Life Sciences AI Implementation begins long before any code is deployed into production systems. In phar...